Dr. Preeti Joseph Thyparampil, MD

Dr. Thyparampil practices at Northwestern Memorial Hospital - Lavin Family Pavilion Recovery Room - HOPD in Chicago, Illinois.

Dr. Thyparampil's NPI, 1760708416, was assigned on April 19, 2010. Dr. Thyparampil graduated from Columbia University College of Physicians and Surgeons in 2010. Dr. Thyparampil holds Illinois license 036141100.

Dr. Thyparampil's primary practice is Northwestern Memorial Hospital - Lavin Family Pavilion Recovery Room - HOPD, at 259 E Erie St, Chicago, IL 60611.

Dr. Thyparampil's primary practice is Northwestern Memorial Hospital - Lavin Family Pavilion Recovery Room - HOPD in Chicago, Illinois. Dr. Thyparampil is also affiliated with Northwestern Memorial Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Thyparampil to 1 more group practice or clinic, named with a free account. Dr. Thyparampil's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Thyparampil practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Thyparampil's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dmand AI has Dr. Thyparampil's licenses on file in 2 states: Illinois and Texas.

CMS data shows 646 Medicare services from Dr. Thyparampil across 10 procedure codes in 2024, for 277 Medicare patients. Medicare paid $58,434 for them.

CMS counts 277 Medicare patients who saw Dr. Thyparampil in 2024. The largest group is 75 to 84, with 117 patients. 75% of them have high cholesterol, and 65% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.08, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Thyparampil's median patient age at 65, with 65% women.

In 2024, Dr. Thyparampil wrote 181 Medicare Part D claims for 96 patients. 85% of them were for generic drugs. CMS names the drug for 134 of them, across 3 drugs with 11 or more claims each, at $4,259 in total drug cost. In 2023, CMS named 68 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Thyparampil for performance year 2024, reported through an alternative payment model (APM). Dr. Thyparampil accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 19 papers to Dr. Thyparampil, published from 2012 to 2025. 2012 was the busiest year, with 2. The most frequent topics are Amoxicillin-Potassium Clavulanate Combination, Biopsy and Dacryocystitis. Dr. Thyparampil has published most often in Ophthalmic Plast Reconstr Surg. Dr. Thyparampil's most frequent co-authors are Michael T. Yen, MD, Paul J. Bryar, MD and Timothy Milton Janetos, MBA, MD.

CMS Open Payments shows 5 general payments to Dr. Thyparampil from 3 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 95% of the total. Horizon Pharma plc paid the most, $332.

Dr. Thyparampil graduated from Columbia University College of Physicians and Surgeons in 2010.